Inactive Instrument

BLACKMORES

Equities

BKL

AU000000BKL7

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kirin Health Science Australia Pty Ltd completed the acquisition of Blackmores Limited from AustralianSuper Pty Ltd., FIL Limited, Marcus Charles Blackmore and others. CI
Blackmores Limited(ASX:BKL) dropped from S&P Global BMI Index CI
Blackmores Limited(ASX:BKL) dropped from S&P/ASX 200 Index CI
Blackmores Limited(ASX:BKL) dropped from S&P/ASX 300 Index CI
Blackmores Limited(ASX:BKL) dropped from S&P/ASX All Ordinaries Index CI
Blackmores Limited(ASX:BKL) dropped from S&P/ASX 200 Consumer Staples Sector Index CI
Blackmores Limited(ASX:BKL) dropped from S&P/ASX Small Ordinaries Index CI
At-home health test maker Thorne explores sale -sources RE
At-home health test maker Thorne explores sale-sources RE
Blackmores Acquisition by Kirin Holdings Takes Legal Effect MT
Blackmores Limited Announces Fully Franked Special Dividend, Payable on 1 August 2023 CI
Japan's Astellas to buy Iveric Bio for $5.9 bln to expand eyesight treatments RE
Japan stocks extend losses as Nomura, Advantest slump after weak results RE
Blackmores Shares Jump 21% on Kirin's A$1.84 Billion Takeover Proposal DJ
Australia shares slip as financials drop on recession fears RE
Japan's Kirin Holdings to acquire Australia's Blackmores for $1.27 billion RE
Kirin Holdings Company, Limited entered into scheme implementation deed to acquire Blackmores Limited for AUD 1.9 billion. CI
Blackmores Recommends A$1.84 Billion Takeover Proposal by Kirin DJ
Blackmores' Net Profit Jumps 20% in Fiscal H1 MT
Blackmores Seeks Acquisitions CI
Transcript : Blackmores Limited, H1 2023 Earnings Call, Feb 23, 2023
Blackmores Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on March 28, 2023 CI
Blackmores Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Blackmores Ceases 1,447 Conditional Rights MT
Bloomberg Video: Blackmores CEO on China Market, New Opportunities MT
Chart BLACKMORES
More charts
Blackmores Limited is an Australia-based natural healthcare company. The Company's principal activity is the development, manufacture, sales, and marketing of health products for humans and animals, including vitamins and herbal and mineral nutritional supplements. Its segments include Australia and New Zealand (ANZ), China, and International. The ANZ segment consists of Blackmores, PAW by Blackmores, Impromy and BioCeuticals practitioner brands sold across Australia and New Zealand, and manufacturing on behalf of third parties within its Braeside facility. The China segment consists of Blackmores brand in China through CBEC (in country), China Export Division, Hong Kong and Taiwan. The International segment consists of Blackmores brands in Thailand, Malaysia, Singapore, South Korea, Indonesia, India, Philippines, Vietnam, and Pakistan. The Company's evidence-based range of brands includes Blackmores, a natural health brand; BioCeuticals, and PAW, a natural health product for pets.
Sector
-
More about the company